Agentic Bioprocessing™
From measurement to meaning to manufacturing intelligence
Agentic Bioprocessing™ is an architecture that lets a manufacturing process interpret its own biology in real time — and act on what it sees. It is built on direct intracellular measurement at single-cell resolution, structured by physics into a form algorithms can reason with and regulators can validate. What follows is the architecture: three layers of biological intelligence, the staged path from deterministic lookup to autonomous control, and the bioprocess applications it serves.
Built from the bottom up
Every intelligence architecture stands on the data beneath it. Agentic Bioprocessing™ stands on a measurement that did not exist before InnoFluidics built it: physics-grounded, intracellular, single-cell, in real time. Every layer of the architecture above this measurement exists because the measurement is sufficient to support it. That sufficiency is not algorithmic. It is physical.
Extracellular process sensors — pH, dissolved oxygen, optical density, Raman — describe the environment cells occupy, not the cells themselves. Any architecture that attempts to reason about cellular biology from that data class hits a ceiling: the biology simply stops being observable. The measurement on which this architecture stands does not have that ceiling. It reads directly inside the cell.
Intelligence is a measurement problem before it is an algorithm problem.
Three layers of biological intelligence
It sees. It understands. It remembers.
Agentic Bioprocessing™ is a stack, not a product. Above the measurement sit three layers — each one a distinct cognitive function, each one built on the layer beneath it. Perception produces the data. Cognition produces meaning from the data. Evolution produces a body of knowledge that outlasts any single batch, site, or deployment. The order is load-bearing: no layer is reachable without the one below it, and no layer is replaceable by the one above.
From the measurement
Stream of single cell events.
1
CDA
Coupled Dispersion Analytics
CDA transforms the instrument's raw electrical measurement into a structured, physics-grounded portrait of intracellular state. The output is the Dispersion Interaction Tensor (DIT) — a high-dimensional representation of what is happening inside each cell, resolved single-cell and single-event. Calibration-free by architecture: the physics of the measurement, not a reference standard, defines the coordinate system.
BIOLOGICAL
PERCEPTION
The Eye
A DIT describes the cell.
Interpretation is the next layer.
2
BBI
Biological Behaviour Interpretation
BBI reads the DIT and answers the questions the measurement alone cannot: what are the cells doing, why, and where is the trajectory heading. The answers are expressed as quantitative Behavioural Indices grounded in biophysics — in the mechanics of the measurement itself, not in statistical correlation over historical batches. When the biology shifts, the indices shift for physical reasons, and the reasons are traceable back to the cell.
BIOLOGICAL
COGNITION
The Mind
Each connected instrument generates these interpretations.
The fleet is what happens next.
3
FBK
Federated Biological Knowledge
Every deployed system contributes to, and draws from, a shared body of biological knowledge. Measurements taken at one site deepen the interpretive capacity available at every other site. Proprietary process data never leaves the site that generated it — only anonymised biological signatures flow into the shared base. The fleet learns across every batch, every modality, every deployment — and the learning persists.
BIOLOGICAL
EVOLUTION
The Memory
Perception produces data. Cognition produces meaning. Evolution produces a knowledge base no single laboratory could build alone.
The path to autonomous bioprocessing
Day 1 value. Progressive autonomy. No regulatory leap.
The architecture arrives as a Day 1 product and grows from there. Three stages, each one a real destination. Regulators are converging on what the next generation of biomanufacturing must demonstrate: real-time process understanding, explainable control, and a documented path from monitoring to autonomy. This roadmap is that path — Day 1 monitoring, continuous evidence generation through normal operation, and autonomous control that is reached only when the evidence supports it.
1
LUT Mode
Day 1 deployment
A deterministic (Look-Up Table) mapping from Behavioural Index combinations to validated biological interpretations. No model drift, no retraining, no AI autonomy. Qualifies under standard IQ/OQ/PQ and delivers its full monitoring value on the first production batch it runs.
2
Shadow Mode
Learning without risk
The interpretation layer runs in parallel with existing process control, logging every prediction and every decision it would have made. It never touches the PLC. Every production batch becomes a validation event — and a contribution to the evidence base for the next stage.
3
Agentic Mode
Bioprocessing 5.0
The system participates in live process control, maintaining a biological narrative rather than following a statistical policy. Control actions are traceable to the biology that called for them. Any parameter outside the validated envelope triggers automatic fallback to Stage 1.
Useful on Day 1. Autonomous when the evidence says so.
One architecture, every major bioprocess
Six modalities. One intelligence stack. Built for all of them.
The same three-layer architecture and the same staged roadmap serve every major biomanufacturing modality — from CHO fed-batch monoclonals to autologous cell therapy, from perfusion to scale-up campaigns. The measurement physics do not care what the cell is. The interpretation layer is configured per modality; the data beneath it is the same.
mAb / CHO Fed-Batch
Predict and manage the metabolic switch preemptively. Reduce batch-to-batch yield variance. Real-time intracellular monitoring across full 14-day run — from inoculation to harvest.
CAR-T & T-Cell Therapy
Confirm activation in real time during expansion. Optimise effector/memory metabolic balance for clinical efficacy. Critical where every patient batch is an independent product.
Perfusion & Continuous Manufacturing
Sustain population health indefinitely. Detect the coupling between optimisation pressure and viability before floor constraints are approached. Continuous manufacturing demands continuous biological visibility.
Scale-Up & Site Transfer
Physics-grounded biological comparability via Dispersion Interaction Tensor fingerprinting. Accelerate comparability assessments across scales and sites. Reduce the one-to-two years of empirical scale-up work that delays every process transfer.
NK Cell & TIL Manufacturing
Monitor cytolytic activation state continuously, not only before harvest. Replace end-of-process offline assays with in-process quality confirmation — on every batch, not only the ones that are sampled.
R&D Process Development
Screen cell lines and media formulations at experiment throughput. Replace offline flow cytometry with real-time intracellular characterisation — during the experiment, not after it.
The biology speaks one language. This platform reads it.
Timing
The science, the regulation, and the economics have converged.
Every technology has a window in which the conditions for its adoption are right. For Agentic Bioprocessing™, that window is open now.
The Science
Single-cell electrical characterisation at the resolution Agentic Bioprocessing™ requires is a recent achievement, not a decades-old capability. Twenty years of dielectric physics, microfluidic engineering, and analytical framework development have produced a platform that reads intracellular state in real time, inside a form factor that qualifies under GMP. The scientific foundation is proven by experimental data and protected by pending patents. The measurement exists now.
The Regulation
Three regulatory frameworks have aligned within the past three years — ICH Q13, the FDA's Predetermined Change Control Plan, and the EMA's AI guidance. Different authorities, different scopes, one direction: real-time process understanding, explainable control, and evidence over outcomes. A physics-grounded, explainable, mechanistically traceable architecture is not an incremental improvement on the current regulatory environment. It is the architecture the regulatory environment has been written for.
The Economics
At €50k—€500k per failed batch and 5%—15% failure rates, the ROI case is unambiguous. The industry’s accelerating shift to continuous manufacturing and cell therapy raises the cost of biological invisibility with every passing quarter. A platform that reads intracellular state in real time is not a productivity improvement. It is a reduction in a failure cost the industry already absorbs — and a prerequisite for the manufacturing formats the industry is already moving toward.
The infrastructure of Bioprocessing 5.0 is being built now, by the first movers. The question is whether you are one of them.
Where it leads
Join us at the beginning.
Agentic Bioprocessing™ is being built now, with a small number of partners who are shaping what the architecture becomes in practice. Behavioural Indices are defined in dialogue with the scientists who will rely on them. Deployment modes are refined against real processes in real facilities. The architecture described on this page is the foundation; what is built on top of it is a shared enterprise. If that is a conversation you want to be part of, please reach out.
Follow us on LinkedIn:
InnoFluidics:
InnoFluidics Diagnostics: